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SUMMARY 
 
Intensity-modulated radiotherapy (IMRT) has been rapidly adopted despite a lack of 
evidence demonstrating superiority over 3D-conformal radiotherapy (3D-CRT). 
A national cohort study using real world data was performed on 23,222 men 
comparing severe gastrointestinal (GI) and genitourinary (GU) toxicity between IMRT 
and 3D-CRT. Men who received radical radiotherapy using IMRT were less likely to 
experience severe GI toxicity and had similar GU toxicity compared to those who 
received 3D-CRT. 
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ABSTRACT 
 
Purpose 
There has been a rapid adoption of Intensity-modulated radiotherapy (IMRT) despite a lack 
of robust evidence demonstrating superiority over 3D-Conformal radiotherapy (3D-CRT). 
The aim of this national population-based study was to compare severe genitourinary (GU) 
and gastrointestinal (GI) toxicity in patients with prostate cancer who were treated with 
radical IMRT or 3D-CRT.  
 
Methods and Materials 
Patients treated with IMRT (n=6,933) or 3D-CRT (n=16,289) between January 1 2010 to 
December 31 2013 in the English National Health Service (NHS) were identified using cancer 
registry data, the National Radiotherapy Dataset and Hospital Episodes Statistics (HES), the 
administrative database of care episodes in NHS hospitals. We developed a coding system 
that identifies severe toxicity (at least Grade 3 according to the NCI CTCAE scoring system) 
based on the presence of a procedure and a corresponding diagnostic code in patients’  HES 
records after radiotherapy. A competing risks regression analysis was used to estimate 
hazard ratios (HR), comparing the incidence of severe GI and GU complications following 
IMRT and 3D-CRT, adjusting for patient, disease, and treatment characteristics.  
 
Results 
The use of IMRT, as opposed to 3D-CRT, increased from 3.1% in 2010 to 64.7% in 2013. 
Patients who received IMRT were less likely than those receiving 3D-CRT to experience 
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severe GI toxicity (4.9 vs 6.5 per 100 person-years; adjusted HR 0.66; 95%CI 0.61-0.72) but 
had similar levels of GU toxicity (2.3 vs 2.4 per 100 person-years; adjusted HR 0.94; 95%CI 
0.84-1.06). 
 
Conclusions 
Prostate cancer patients who received radical radiotherapy using IMRT were less likely to 
experience severe GI toxicity and they had similar GU toxicity compared to those who 
received 3D-CRT. These findings in an unselected “real-world” population support the use of 
IMRT, but further cost-effectiveness studies are urgently required. 
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INTRODUCTION 
 
External beam radiotherapy (RT) is a well-established definitive treatment for localised and 
locally advanced prostate cancer. Dose-escalation to the tumour has been shown to 
improve biochemical progression-free survival however this can be at the cost of increased 
gastrointestinal (GI) and genitourinary (GU) side effects (1-4). GI toxicity can occur in the 
acute phase typically within 3 months caused by a mucosal inflammatory response and in 
the late phase characterised by fibrotic changes resulting in chronic GI impairment (5). 
Similarly, GU side effects such as haematuria can occur soon after treatment whereas 
bladder outflow obstruction and radiation cystitis may occur later (6). 
 
Attempts to improve the therapeutic ratio, in particular a reduction in treatment related 
side effects, has driven advances in modern radiotherapy technologies such as Intensity-
modulated radiotherapy (IMRT) (4). The advantage of IMRT compared to 3D-conformal 
radiotherapy (3D-CRT) is the potential to deliver high-dose radiation to the prostate (7, 8), 
whilst limiting the radiation dose to surrounding tissue including the rectum and bladder, 
reducing acute and late toxicities (9-12). 
 
IMRT was taken up rapidly from the early 2000s in the United States and then in the United 
Kingdom (13) at considerable cost (14) in the absence of robust RCT evidence demonstrating 
its superiority over 3D-CRT (15). A recent meta-analysis, including 23 clinical studies with 
9,556 patients, demonstrated that the use of IMRT greatly reduced acute and late GI toxicity 
(16). This also suggested that IMRT was linked to a small increase in acute GU toxicity and a 
small reduction in biochemical failure (i.e. rise of prostate-specific antigen level of 2 ng/ml 
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or more). However, the authors of this meta-analysis highlighted the heterogeneity of the 
results and that more high-quality studies were needed. 
 
The rapid adoption of IMRT means that future RCTs assessing its effectiveness are no longer 
feasible. However, “real-world” data provides an opportunity to understand the true value 
of IMRT compared to 3D-CRT. We carried out a national population-based study including 
more than 23,000 men diagnosed with prostate cancer between 2010 and 2013 in the 
English National Health Service, who received either IMRT or 3D-CRT. We used a coding 
system that was specially developed to identify severe toxicity, comparable to at least Grade 
3 toxicity as measured by NCI Common Toxicity Criteria for Adverse Events (CTCAE) scoring 
system (version 4.0) (17), in administrative hospital data. 
 
 
METHODS 
 
Data Sources and Patient population 
English cancer registry data and the National Radiotherapy Dataset were used to identify 
men with a diagnosis of prostate cancer (ICD-10 “C61”) who received radical radiotherapy 
between 1 January 2010 and 31 December 2013 (18). These men were linked to the Hospital 
Episode Statistics (HES) database, an administrative database of all care episodes in the 
National Health Service in England (19). 
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Control variables 
Data items in HES records were used to determine age, the Royal College of Surgeons (RCS) 
Charlson comorbidity score expressed as the number of comorbidities (20), and 
socioeconomic deprivation status according to quintiles of the national ranking of the Index 
of Multiple Deprivation (21). Tumour characteristics including TNM-stage and Gleason score 
were extracted from the cancer registry data to determine a modified D’Amico prostate 
cancer risk classification (a previously developed algorithm to group patients according to 
pre-treatment prostate cancer risk in the absence of data on prostate-specific antigen 
levels) (13). The National Radiotherapy Dataset provided information on the radiotherapy 
treatment region (prostate only/prostate and regional), whether or not an IMRT technique 
was used (OPCS-4 code “X671”) (22), and the total prescribed dose/fractions. 
 
Inclusion and exclusion criteria 
The records of 41,763 men with non-metastatic prostate cancer who had received 
radiotherapy were studied. Patients were excluded if they had also received brachytherapy 
(n=165), if they had an associated diagnosis of bladder cancer (ICD-10 “C67”) (n= 1,103) 
(23), or if they received radiotherapy following radical prostatectomy (n= 3,341). As this 
study used national data, variation existed in the fractionated regimes delivered. With 
reference to UK radiotherapy dose fractionation guidance and regimes used in randomised 
controlled trials (3, 24-27), we included patients who received 72-79 Gy in 35-40 fractions. 
The three further regimes that were most commonly used were also included (72 Gy/32 
fractions; 69 Gy/37 fractions; 70 Gy/35 fractions). This resulted in the exclusion of a further 
13,932 men. The final cohort included 23,222 men (Figure 1). 
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Coding Framework 
We have previously developed and validated a method using linked administrative data to 
identify severe GU complications following radical prostatectomy (28). This methodological 
approach was used to capture severe urinary complications after radiotherapy. With 
reference to earlier studies which used procedure codes to measure toxicity (11, 29, 30), a 
comprehensive list of OPCS-4 procedure codes (22) related to GU complications post-RT was 
pre-specified (“forward coding”). We also examined the most frequently occurring 
procedure codes in records of day-case and in-patient hospital episodes following 
radiotherapy and added these to the pre-specified list if they were not already included but 
likely to be related to GU complications (“backward coding”) (Appendix, Table i). 
 
The forward and backward coding approach was repeated to identify ICD-10 diagnostic 
codes related to urinary complications. In addition to a “radiation-specific” code (N304, 
“irradiation cystitis”) we also captured other common side effects including haematuria, GU 
strictures and urinary incontinence (Appendix, Table ii). The GU toxicity outcome measure 
was defined as the occurrence of both a procedure and corresponding GU diagnostic code in 
a patient record following the first radiotherapy treatment session. This approach confined 
our analyses to what were likely to be more severe complications, comparable to at least 
Grade 3 toxicity as measured by NCI Common Toxicity Criteria for Adverse Events Scoring 
system (i.e. requiring hospital admission or procedural intervention) (17). 
 
For GI toxicity after radiotherapy, we also determined a list of procedure and diagnostic 
codes based on previous studies (Appendix Table iii/iv) (11, 29, 30). ICD-10 diagnostic codes 
included “radiation-specific” codes (K520 “gastroenteritis and colitis due to radiation”; K627 
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“radiation proctitis”) as well as those likely to be a GI complication of radiation such as 
rectal bleeding and fistulae formation (Appendix Table iv). Just as for GU toxicity, we defined 
the GI toxicity outcome measure, also capturing Grade 3 or higher toxicity, as the 
occurrence of both a procedure and corresponding GI diagnosis code to be present in a 
patient record. This was important as it excluded men who underwent procedures such as a 
“colonoscopy” for other reasons not related to post-RT GI toxicity. 
 
Time from date of the first radiotherapy treatment to the first GU or GI complication 
requiring an intervention were the study primary outcomes. For both outcomes, if more 
than one procedure code matched to a corresponding diagnosis code in the patient record, 
then the code in the first procedural field was used as it was most likely to represent the 
most relevant procedure. Patients were considered as not having experienced GU or GI 
toxicity if there were no day-case or in-patient hospital episodes from the first date of 
radiotherapy until the end of follow-up (31 December 2015). 
 
Statistical Analysis 
Differences between patient, disease and treatment characteristics were assessed using the 
χ
2
 test. The 5-year cumulative incidence of complications was estimated using a competing-
risks approach (31). To be consistent with existing literature (32), for each outcome measure 
we calculated the number of events per 100 person-years of follow-up. This metric provided 
a single figure for the rate of GU and GI complications in both groups. 
 
A competing-risks regression analysis was used to compare time to complication between 
IMRT and 3D-CRT groups, with complication as the event of interest and death as the 
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competing event. We adjusted for year of radiotherapy, age, RCS Charlson comorbidity 
score, socioeconomic deprivation status, prostate cancer risk group, and radiotherapy 
treatment region. 
 
Results are reported as adjusted hazard ratios (HR) with 95% confidence intervals (95%CI). A 
p-value smaller than 0.05 was considered statistically significant. P-values were based on 
the Wald test or the likelihood ratio test, as appropriate. 
 
Prior to the regression analysis, missing values for prostate cancer risk group (n= 5,753), 
radiotherapy treatment region (n=3,793), and socioeconomic deprivation status (n=61) 
were imputed using multiple imputation by chained equations. We created 50 datasets and 
used Ruben’s rules to combine the estimated hazard ratios across the datasets (33). The 
distribution of patients in categories did not change significantly after multiple imputation. 
 
 
RESULTS 
 
Patient population 
Among the patients who received radical radiotherapy (n=23,222), the use of IMRT 
increased from 3.1% in 2010 to 64.7% in 2013 (Table 1). Approximately 60% of men included 
were between 65 to 74 years old, about 1 in 5 men had at least one recorded comorbidity, 
and nearly 60% of patients were staged with locally advanced disease. The median dose per 
fraction and total dose received were the same in both groups (2 Gy/fraction and 74 Gy, 
respectively). Men in the 3D-CRT group were more likely to be older and have a RCS 
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Charlson score ≥1, but were less likely to have locally advanced disease and receive 
radiation to the prostate and nodes compared to the IMRT group (Table 1). Median (IQR) 
follow-up was 3.6 (1.9) years for all men in the study; 2.7 (1.0) years for the IMRT group and 
4.1 (1.6) years for the 3D-CRT group. 
 
Timing and frequency of occurrence of toxicity 
The most frequent intervention for GI toxicity was a “diagnostic fibreoptic sigmoidoscopy” 
(3,607 of 9,300 procedures, 38.8%) and the commonest associated GI diagnosis was 
“radiation proctitis” (5,962 of 8,701 diagnoses, 68.5%). For GU toxicity, an “unspecified 
endoscopic examination of the bladder” (1,470 of 3,625 procedures, 40.6%) was the most 
frequent intervention and “haematuria” was the most common associated GU diagnosis 
(1,265 out of 4,061 diagnoses, 31.1%) (Appendix, Tables i-iv). 
 
Patients experienced 4.9 GI events per 100 person years of follow-up in the IMRT group 
compared to 6.5 in the 3D-CRT group (Table 2). Patients who received IMRT experienced 2.3 
GU events per 100 person years of follow-up compared to 2.4 in the 3D-CRT group (Table 2). 
 
Cumulative incidence curves showed GI toxicity was low in the first 9 months (≈2%) and 
similar in the IMRT and 3D-CRT groups (Figure 2). However, beyond 9 months after RT, 
patients in the 3D-CRT group more frequently had complications than the IMRT group. 
Conversely, GU toxicity steadily increased in both IMRT and 3D-CRT groups following radical 
radiotherapy (Figure 2). 
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Outcome Measures 
Adjusting for patient, disease, and treatment characteristics and using a competing-risks 
approach, we found that men treated with IMRT were less likely to experience GI toxicity 
(HR: 0.66, 95% CI: 0.61-0.72; p<0.01) than those who received 3D-CRT. There was no 
significant difference in GU toxicity between the groups (HR: 0.94; 95% CI: 0.84-1.06; 
p=0.31). (Table 2) (Appendix, Table v – competing-risks regression analysis with all variables) 
 
 
DISCUSSION 
 
Summary 
Using outcome measures that were systematically developed, we demonstrated a 
significantly lower incidence of severe GI toxicity and a similar incidence of severe GU 
toxicity in men who received IMRT compared to those who received 3D-CRT. This is the 
largest study comparing treatment-related complications in patients receiving IMRT or 3D-
CRT. It used “real-world” data from a national population-based cohort without excluding 
patients based on age or socioeconomic status. 
 
We have used outcome measures, specifically designed to capture urinary complications 
severe enough to require an intervention and comparable to at least Grade 3 toxicity (NCI 
CTCAE scoring system). This is in contrast to all other studies using existing routine data (11, 
34, 35) that used discrete diagnosis, procedure and claims codes without explicitly 
developing these codes as toxicity outcomes measures for a specific level of severity. A 
further strength of our study was the availability of data on radiation doses and fractions 
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received by patients within the National Radiotherapy Dataset, which was not present in 
previous studies (8, 11, 30). This ensured that only recognised fractionated regimes were 
included and that patients in both IMRT and 3D-CRT groups received comparable radiation 
doses, which are often confounders in population-based studies. 
 
Comparison with other studies 
The previous largest comparative study of IMRT and 3D-CRT using existing routine data 
reported on approximately 13,000 men who received treatment between 2002 and 2006 
(11), based on SEER-Medicare-linked data. Similar to our study findings, men who received 
IMRT were less likely to have GI toxicity and there was no difference between the groups in 
GU toxicity. This study found a higher incidence of GI toxicity after 3D-CRT than after IMRT 
when considering GI diagnoses in both groups, but this was not the case when considering 
GI procedures. This discrepancy is to be expected given the use of toxicity based on 
diagnosis codes and procedure codes in isolation. In contrast, our study required the 
presence of a diagnosis and procedure code to ensure we captured complications 
comparable to Grade 3 toxicity or higher. 
 
Our findings are similar to those reported in the recent meta-analysis (16) which found that 
IMRT had a lower incidence of acute and late GI toxicity. This meta-analysis also found a 
very small increase in acute GU toxicity after IMRT which was not observed in our study. It is 
important to note that in most of the studies included in the meta-analysis, patients in the 
IMRT group received a higher total radiation dose than the 3D-CRT group. A strength of our 
study is that both groups received comparable radiation doses. 
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We adjusted the comparison of the incidence of complications in men who received IMRT or 
3D-CRT for differences in patient, disease, and treatment characteristics. However, we were 
not able to control for baseline GI and GU symptoms which could have an impact on post-RT 
toxicity. Furthermore, we could not control for additional therapeutic differences, including 
the use of image-guided radiotherapy (IGRT), the use of specific bladder or bowel 
preparation protocols, radiotherapy field size, or the use of hormonal treatment. For 
example, the use of IGRT reduces GI and GU toxicity (36) and is more likely to have been 
used in IMRT patients. If this is the case, our study may have overestimated the relative 
benefit of IMRT. Information on the use of hormonal therapy was also not available 
although results from previous studies demonstrate that hormonal therapy was not 
associated with the incidence of GI or GU toxicity (16, 37). Despite the absence of 
information on radiotherapy field size, we were able to account for whether men received 
treatment to the prostate alone or to the pelvis. At the time of this study, the last follow-up 
date within our database was the 31
st
 December 2015 therefore we were not able to report 
on longer-term GI and GU toxicity – future studies will aim to address long-term RT-related 
toxicity. 
 
As the use of IMRT compared to 3D-CRT increased during our study period, the median 
length of follow-up was higher in the latter. Although we adjusted for year of treatment in 
the regression model, we also performed a sensitivity analysis only including men who 
received RT in 2012 and 2013, all of whom had at least 2-years of follow-up. The results of 
this sensitivity analysis fully supported the findings from the primary analysis.  
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Clinical Implications 
Our findings are in line with the notion that IMRT allows the delivery of higher doses while 
reducing exposure to the rectum and in turn reducing GI toxicity. Furthermore, this 
reduction occurred despite a higher proportion of patients in the IMRT group receiving 
additional pelvic radiotherapy compared to the 3D-CRT group. The benefits of IMRT, 
however, do not appear to lead to a reduction in GU toxicity. A potential explanation for this 
is that the benefits of IMRT may be countered by the high variability in patients’ bladder 
capacity and filling volumes. These findings are supported by other dosimetric studies which 
have shown that rectal sparing is better with IMRT than with 3D-CRT but that the 
differences for bladder sparing may not be as significant (8) (38). 
 
Given the substantial increased costs associated with delivering IMRT (39), further studies 
are required to evaluate the cost-effectiveness of IMRT in light of its improved toxicity 
profile with respect to severe GI toxicity. This is of particular relevance in low and middle-
income countries where there is an urgent need for expansion in access to radiotherapy 
(40). The lack of robust comparative clinical data has meant that the benefit from IMRT in a 
cost-effectiveness model remains uncertain, particularly the estimation of the incidence of 
toxicity following treatment (41). The morbidity outcomes from our study provide further 
means to strengthen economic models using existing administrative data. 
 
Conclusion 
In this national population-based study of patients with non-metastatic prostate cancer, we 
have shown that men who received radical radiotherapy using IMRT were less likely to 
experience severe GI toxicity and that they had similar severe GU toxicity compared to those 
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who received 3D-CRT. Our study used a transparent coding system that was specifically 
developed to identify only severe complications. This coding system can be used to provide 
a performance indicator for service evaluation and quality assessment. Furthermore, it can 
be used for comparative effectiveness research using existing administrative data to capture 
GU and GI toxicity following pelvic-based radiotherapy of other tumours such as cervical 
cancer. 
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Table 1: Patient, disease and treatment characteristics of men receiving 
radical radiotherapy (number and percentages) 
 
 
 3D-CRT(n= 
16,289) 
IMRT(n= 6,933) p Value 
Year of radiotherapy    
2010 4,248 (26.1)  216 (3.1) <0.01 
2011 5,159 (31.7)  624 (9.0)  
2012 4,678 (28.7)  1,605 (23.1)  
2013 2,204 (13.5)  4,488 (64.7)  
    
Age    
<60 1,069 (6.5) 532 (7.7) <0.01 
60-64 2,409 (14.8) 1,096 (15.8)  
65-74 9,311 (57.2) 3,879 (56.0)  
>75 3,500 (21.5) 1,426 (20.6)  
    
RCS Charlson comorbidity 
score 
   
0 12,407 (76.2) 5,463 (78.8) <0.01 
≥1 3,882 (23.8) 1,470 (21.2)  
    
Socioeconomic deprivation 
status (national quintiles) 
   
1 (least deprived) 3,683(22.6) 1,649 (24.0) 0.19 
2 4,063(25.0) 1,735 (25.2)  
3 3,552 (21.8) 1,471 (21.4)  
4 2,707 (16.6) 1,112 (16.2)  
5 (most deprived) 2,270 (14.0) 919 (13.4)  
Missing 14 47  
    
Prostate cancer risk group    
Locally Advanced 6,433 (56.4) 3,603 (59.4) <0.01 
Intermediate risk localised 4,433 (38.9) 2,211 (36.4)  
Low-risk localised 534 (4.7) 384 (5.3)  
Missing 4,889 864  
    
Radiotherapy treatment 
region 
   
Prostate 11,782 (72.3) 5,786 (86.4) <0.01 
Prostate & Regional 950 (5.8) 911 (13.6)  
Missing 3,557 236  
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Table 2: Adjusted outcomes for gastrointestinal and genitourinary toxicity following 
radical radiotherapy 
 
 GI Toxicity GU Toxicity 
 5-year 
cumulative 
incidence % 
(95% CI) 
Rate (total 
events/100 
person 
years) 
HR* (CI) p-
value 
5-year 
cumulative 
incidence % 
(95% CI) 
Rate (total 
events/100 
person 
years) 
HR* (CI) p-
value 
3D-CRT 
 
24.5 (23.8-25.3) 6.5 1.00 - 11.1 (9.2-13.3) 2.4 1.00 - 
IMRT 
 
17.0 (15.6-18.5) 4.9 0.66 (0.61-0.72) <0.01 10.7 (10.1-11.3) 2.3 0.94 (0.84-1.06) 0.31 
 
*Adjusted for year of radiotherapy treatment, age, RCS Charlson comorbidity score, socioeconomic deprivation 
status, prostate cancer risk group and radiotherapy treatment region  
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Figure 1: Flow chart of men included in study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Included fractionated regimes:  
 
Regimen (Dose (Gy)/Fractions) No. of patients 
72-79/35-40  21,046 
72/32 1439 
70/35 443 
69/37 294 
 
 
 
Radical radiotherapy  
cohort 
 
23,222 
 
Clinical exclusions (n=18,541) 
 
 165 men excluded who also 
received brachytherapy 
 
 1,103 men excluded with 
additional diagnosis of bladder  
 
 3,341 men who received 
radiotherapy after radical 
prostatectomy 
 
 13,932  men excluded who did not 
receive a recognised fractionated 
regime*  
 
 
 
Men receiving radical radiotherapy (2010-2013) 
(non-metastatic prostate cancer) 
 
41,763 
 
 
Clinical Exclusions (n=10,220) 
 
 165 men excluded who also received Brachytherapy 
 
 1,103 men excluded with additional diagnosis of 
bladder  
 
Men receiving Radical Radiotherapy from 2010-
2013 (non-metastatic PCa) 
(RTDS/CR/HES) 
41,763 
 
 
Clinical Exclusions (n=10,220) 
 
 165 men excluded who also received Brachytherapy 
 
 1,103 men excluded with additional diagnosis of 
bladder  
 uded with additional diagnosis of bladder  
en receiving radical radiotherapy from    
2010-2013 (non-metastatic PCa) 
(RTDS/CR/HES) 
41,763 
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Figure 2 Cumulative incidence curves for gastrointestinal toxicity (upper figure) and 
genitourinary toxicity (lower figure) following radical radiotherapy according to type of 
radiotherapy (IMRT versus 3D Conformal RT) 
 
  
 
 
 
 
 
 
 
 
Numbers at risk 
Time 
(years) 
0 1 2 3 4 5 
3D-CRT 16,289 15,127 13,075 10,431 6,531 2,817 
IMRT 6,933 6,598 6,010 1,997 649 170 
Numbers at risk 
Time 
(years) 
0 1 2 3 4 5 
3D-CRT 16,289 15,640 14,923 12,276 7,834 3,373 
IMRT 6,933 6,696 6,404 2,177 717 171 
